Layoffs Begin at U.S. Public Health Agencies

The Department of Health and Human Services (HHS) layoffs are part of a plan to eliminate 10,000 jobs, which comes after 10,000 workers had already accepted early retirement or voluntary separation offers. This overhaul is projected to reduce the department's total staff to 62,000, a decrease of nearly a quarter. The cuts are distributed across key agencies: the Food and Drug Administration (FDA) is set to lose 3,500 positions, the Centers for Disease Control and Prevention (CDC) will cut 2,400 jobs, and the National Institutes of Health (NIH) will slash 1,200. The administration claims these reductions will save $1.8 billion annually from the department's $1.7 trillion budget. At the CDC, entire programs have been eliminated, including those focused on smoking, lead poisoning, occupational safety, and gun violence. Additionally, the Division of HIV Prevention had half of its staff receive layoff notices, and the center focused on HIV, Hepatitis, STDs, and Tuberculosis prevention has been cut. The NIH, the nation's primary agency for biomedical research, has seen nearly 800 research projects cut and at least four directors of its 27 institutes and centers placed on administrative leave. Experts warn these cuts could stall the development of new therapies and slow scientific innovation. The layoffs are part of a larger restructuring effort to consolidate some functions under a new "Administration for a Healthy America". This follows years of public health advocates warning about chronic underfunding and a potential "funding cliff" after the COVID-19 pandemic emergency. Experts fear the workforce reduction will weaken the country's ability to respond to future health crises and delay the approval of lifesaving drugs. The cuts impact a wide range of personnel, including researchers, scientists, doctors, and senior leaders who guide U.S. decisions on medical research and drug approvals.